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Abstract 
Objective:  Although electronic cigarettes (e-cigarettes) are frequently initiated for smoking 
cessation, results from the first two clinical trials testing this suggest that the perceived benefits 
of vaping may be influenced by non-nicotine factors, including cognitive outcome expectancies. 
The current study investigated the separate and combined effects of nicotine delivery and 
outcome expectancies on cravings for cigarettes and e-cigarettes using a balanced-placebo 
experiment. Method:  Drug dosage (contains nicotine or not) was crossed with instructional set 
(told nicotine or non-nicotine) during ad-lib e-cigarette use sessions by 128 current e-cigarette 
users (52 identifying as current cigarette smokers, or “dual users”). It was hypothesized that 
reduction in craving for both cigarettes and e-cigarettes following e-cigarette administration 
would be driven primarily by the instructional set manipulation, reflecting the influence of 
outcome expectancies. Results: As hypothesized, among dual users, a main effect of 
instructional set emerged on reductions in craving to smoke cigarettes, with participants who 
were told that their e-cigarette contained nicotine reporting greater craving reduction (p = .046). 
With respect to reduced cravings for e-cigarettes, we found an interaction between drug dose and 
instructional set (p = .02) such that nicotine e-cigarettes reduced cravings more than non-nicotine 
e-cigarettes only among participants told to expect nicotine.  Conclusions: Findings suggest that 
cognitive expectancies contribute to the acute effects of e-cigarettes on craving, which may 
provide guidance for their potential as smoking cessation aids.   
Keywords: e-cigarette, cigarette, smoking, expectancies, balanced-placebo, nicotine 
Public Health Impact: This study demonstrated that use of an electronic cigarette may reduce 
nicotine craving (i.e., desire to smoke or vape) via nonpharmacological routes, including beliefs 
about nicotine, rather than simply via nicotine delivery itself.  This finding has implications for 
understanding e-cigarette use as well as its potential as a smoking cessation aid.
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Recently, there has been a shift in the landscape of tobacco use with the introduction of 1 
novel products such as electronic cigarettes (e-cigarettes), which are portable, battery-powered 2 
devices containing a heating element that aerosolizes a liquid solution. Using e-cigarettes is often 3 
referred to as “vaping,” and users may self-identify as “vapers.” It has been estimated that 2.4% 4 
of US adults use e-cigarettes regularly, with the vast majority being current or former smokers 5 
(Zhu, Zhuang, Wong, Cummins, & Tedeschi, 2017). Vapers report that their primary reason for 6 
using e-cigarettes is to quit or reduce smoking of traditional, combustible cigarettes (e.g., Siegel, 7 
Tanwar, & Wood, 2011). To date, only two double-blind randomized controlled trials (RCTs) of 8 
e-cigarettes for smoking cessation have been published. One study (Bullen et al., 2013) randomly 9 
assigned transdermal nicotine patches, nicotine e-cigarettes, and placebo (non-nicotine) e-10 
cigarettes to participants interested in quitting smoking. Another trial (Caponnetto et al., 2013) 11 
randomized non-treatment seeking participants to receive one of two nicotine doses or placebo e-12 
cigarettes. Although both trials indicated that e-cigarettes were effective in promoting smoking 13 
reduction or cessation, no significant differences were found based on nicotine content.  14 
Cravings to use a drug are often considered the final common pathway in theoretical 15 
models of drug use motivation (Baker, Morse, & Sherman, 1986). In the case of tobacco 16 
smoking, the FDA-approved medications (NRTs, bupropion, and varenicline) have all been 17 
shown to reduce cue- and abstinence-induced cravings to smoke in laboratory paradigms 18 
(Ferguson & Shiffman, 2009).  In addition, research has found that e-cigarette use reduces 19 
cravings to smoke and to vape, with mixed evidence regarding the role of nicotine per se 20 
(Dawkins, Turner, Hasna, & Soar, 2012; Perkins, Karelitz, & Michael, 2017).  There is also 21 
some evidence that the sensorimotor aspects of vaping (i.e., its similarity to smoking behavior) 22 
contributes to craving reduction (Van Heel, Van Gucht, Vanbrabant, & Baeyens, 2017). 23 
Drug use and addictive behaviors may also be influenced by outcome expectancies, 24 
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which are learned, cognitive intervening variables. Drug-related expectancies refer to the degree 25 
that individuals expect positive and negative outcomes from drug use.  Expectancies have been 26 
predictive of initiation, maintenance, cessation, and relapse to alcohol, tobacco, and other 27 
substances (Brandon, Juliano, & Copeland, 1999; Goldman, 1999).  Research on expectancies 28 
for e-cigarette use has been limited to survey data (e.g. Harrell, Marquinez et al., 2015).   29 
Prior studies have indicated that expectancies can sometimes influence immediate drug 30 
use behaviors and outcomes to a greater degree than drug dosage itself (Kirsch, 1985)—often 31 
referred to as “the placebo effect.” This phenomenon has been studied through simultaneous 32 
expectancy and pharmacological manipulation using the balanced-placebo design (BPD), 33 
initially to study the effects of alcohol (Hull & Bond, 1986; Marlatt, Demming, & Reid, 1973), 34 
and more recently with tobacco and NRT (Dar & Barrett, 2014; Juliano & Brandon, 2002). This 35 
paradigm utilizes a 2x2 factorial design in which drug type (active or placebo) is crossed with 36 
instructional set (told active or placebo). From this, the effects of both the pharmacologic 37 
properties of the drug and expectancies about the drug can be independently evaluated as causal 38 
influences. In general, the results from these studies demonstrate that active drug delivery 39 
appears to have primary influence over physiological or objective domains, whereas drug 40 
expectancies may influence more emotionally salient or subjective domains, such as craving. 41 
These effects have been observed in both laboratory studies and more naturalistic field studies 42 
(Dar & Barrett, 2014). Thus, the BPD can be used to test the independent and synergistic effects 43 
of nicotine delivery and nicotine expectancies upon craving reduction. 44 
The primary goal of the present study was to investigate the effects of nicotine and 45 
expectancies on cravings to smoke and cravings to vape.  Current e-cigarette users were 46 
randomized to use e-cigarettes that contained either nicotine or non-nicotine solutions, and were 47 
E-CIGARETTE BALANCED PLACEBO DESIGN   5 
independently instructed that the e-cigarette contained nicotine or non-nicotine, resulting in four 48 
experimental conditions as illustrated in Table 1. It was hypothesized that instructional set should 49 
produce differences in craving reduction such that told nicotine would produce greater reduction 50 
in craving than told no-nicotine, reflecting the role of nicotine-related expectancies. There were 51 
no a priori hypotheses regarding main effects of nicotine content or interactions.  52 
Method 53 
Participants  54 
Participants were 130 individuals recruited primarily from flyers at local vape shops 55 
(Table 2). Participants were screened by telephone for the following eligibility criteria: 1) > 18 56 
years old; 2) Current e-cigarette users (daily nicotine solution use for > 30 days); 3) History of 57 
cigarette smoking (> 100 lifetime cigarettes; > 1 cigarette/day for > 30 days); 4) No current e-58 
cigarette cessation attempt; and 5) Not currently pregnant, attempting to get pregnant, or nursing. 59 
Experimental Procedure 60 
Eligible participants were asked to abstain from using e-cigarettes and combustible 61 
cigarettes for three hours prior to the session. To increase adherence, participants were told that a 62 
breath carbon monoxide (CO) reading would be administered. Upon arrival, research staff 63 
obtained written informed consent, and then collected the CO sample (M = 12.63, SD = 8.63 64 
ppm among smokers; M = 6.00, SD = 4.21 ppm among former smokers). Participants were then 65 
randomized to condition and their e-cigarette solution prepared by a researcher with no 66 
participant contact, ensuring a double blind for the drug manipulation. Randomization used a 4-67 
block pattern with stratification based on sex, cigarette smoking status (current [defined by 68 
smoking >1 cigarette per week] or former), and flavor preference (tobacco, menthol, or fruit).  69 
Participants completed demographic and baseline measures, followed by the first 70 
E-CIGARETTE BALANCED PLACEBO DESIGN   6 
administration of craving measures. Participants were then provided an e-cigarette with 71 
instructions and labeling consistent with the instructional set conditions. They were instructed to 72 
take at least 10 puffs over the 10 minute session. Following the ad-lib session, the craving 73 
measures were re-administered. (Secondary outcome variables—affect, appetite, reinforcement, 74 
and attention—were then collected and will be reported elsewhere.) 75 
Apparatus  76 
Participants were provided with an eGo-style 3.6-4.2 Volt, 1100 mAh battery with a 2.8-77 
Ohm, 510-style clearomizer. This device contained an LCD display showing number of puffs. 78 
This e-cigarette style is considered “second generation,” which deliver nicotine more 79 
consistently and are preferred among experienced vapers compared to first generation “cig-a-80 
like” styles (e.g., Dawkins, Kimber, Puwanesarasa, & Soar, 2015). 81 
The solution used was a 50% vegetable glycerin (VG), 50% propylene glycol (PG) 82 
liquid. Target nicotine content was either 0 mg/ml or 12 mg/ml, with the latter having produced 83 
similar plasma nicotine concentrations (as measured in venous blood samples) as traditional 84 
cigarettes (Ramôa et al., 2015). Participants were given the choice of tobacco, menthol, or fruit 85 
flavors. This solution was a custom-made “research blend” (Avail Vapor, LLC). The solutions 86 
were retested using mass spectrometry and liquid chromatography, which verified that the non-87 
nicotine solutions contained 0 mg/ml nicotine.  Final concentrations of the nicotine solutions 88 
were 11.2 mg/ml (tobacco), 10.3 mg/ml (menthol), and 10.0 mg/ml (fruit).  89 
Assessments 90 
Baseline assessments.  Participants completed questionnaires capturing basic 91 
demographic information, smoking and vaping history, and device preference. Dependence on e-92 
cigarettes was measured using the Penn State Electronic Cigarette Dependence Index (ECDI; 93 
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Foulds et al., 2014; α = 0.70), whereas cigarette dependence was measured with the Fagerström 94 
Test for Nicotine Dependence (FTND; Heatherton, Kozlowski, Frecker, & Fagerström, 1991; α 95 
= 0.56 for current smokers).  96 
Craving to smoke and craving to use e-cigarettes. A 3-item adaptation of the 97 
Questionnaire of Smoking Urges-Brief (QSU; Cox, Tiffany, & Christen, 2001; Kozlowski, 98 
Pillitteri, Sweeney, Whitfield, & Graham, 1996) was used to assess craving to smoke (α = 0.90 - 99 
0.95) and craving to vape (α = 0.91 - 0.94). The items, assessing “desire,” “craving,” and 100 
“wanting,” were rated 0-6, yielding scores from 0-24.    101 
Nicotine dosing estimate. As a check on the instructional set manipulation, participants 102 
completed a brief questionnaire post ad-lib session asking them to estimate the nicotine dose of 103 
the provided e-cigarette (0mg/ml, 6mg/ml, 12 mg/ml, 18 mg/ml, or 24 mg/ml).  104 
Data Analysis Plan 105 
 Factorial 2 X 2 analyses of variances (ANOVAs) and χ2 tests were used to test for 106 
baseline differences between factorial conditions (drug, instructional set). T-tests were used to 107 
test for baseline differences by sex and smoking status.  Next, 2 (drug) X 2 (instructional set) X 2 108 
(sex) ANOVAs were used to test the main effects and interactions of the drug and instructional 109 
set manipulations on pre-to-post changes in craving. Given previous sex differences found on 110 
both general nicotine effects (Perkins, 1996) and e-cigarette outcome expectancies (Copp et al., 111 
2015; Piñeiro et al., 2016), sex was included as a third factor.  112 
RESULTS 113 
Preliminary Analyses 114 
Two participants were removed (instructional non-compliance, incorrect randomization) 115 
from final analyses N (= 128). Drug X instructional set ANOVAs failed to reveal significant 116 
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differences between conditions on any demographic, baseline, pre-test variables, or puff count. 117 
No differences were found between sexes on pre-ad-lib outcome variables. Current smokers and 118 
former smokers were compared on several descriptive variables, as shown in Table 3.  119 
Craving Reduction 120 
Cravings to smoke.  Among current smokers (n = 52), the hypothesized main effect of 121 
instructional set was observed on change in craving to smoke as measured by the QSU, F (1, 44) 122 
= 4.21, p = .046, η2 = 0.09. Greater craving reduction was found among those told they received 123 
nicotine (M = 7.92, SD = 6.59) than those told they did not receive nicotine (M = 4.25, SD = 124 
5.31; see Table 4 and Figure 1). No main effect of drug was found, nor were there interactions 125 
between instruction, drug, or sex.  126 
Craving to vape.  Using the full sample, no main effects of drug, instructional set, or sex 127 
emerged, but a significant drug X instructional set interaction was found on craving to vape, F 128 
(1, 120) = 5.56, p = .020, η2 = 0.04 (see Figure 2).  Post-hoc analyses revealed a significant effect 129 
of nicotine dose only when participants were told to expect nicotine, t (62) = -2.75, p = .008, d = 130 
.69.  Additional paired-comparisons revealed that the True Positive group showed significantly 131 
greater reductions in craving to vape than the Placebo group, t (61) = -2.57, p = .013, d = .65, and 132 
the Anti-Placebo group, t (62) = -2.75, p = .008, d = .69, and marginally greater than the True 133 
Negative group t (63) = -1.96, p = .05, d = .49.  134 
Nicotine Dosing Estimate 135 
A 2x2 ANOVA revealed main effects of both instruction (F [1, 124] = 47.17, p < .001) 136 
and drug content (F [1, 124] = 15.71, p < .001) on estimated nicotine content. Told nicotine 137 
produced higher nicotine estimates (M = 10.98, SD = 6.64 vs M = 4.12, SD = 5.24), as did actual 138 
nicotine content (M = 9.50, SD = 7.56 vs M = 5.50, SD = 5.47).  139 
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To further explore the relationship between perceived nicotine dose and craving relief, 140 
correlations between these variables were examined.  Among smokers, higher nicotine dose 141 
estimates were associated with greater cigarette craving reduction, r (50) = .37, p = .007. Among 142 
the full sample, nicotine dose estimate was not associated with e-cigarette craving reduction, r 143 
(126) = .15, ns.   144 
DISCUSSION 145 
 This study aimed to address specific motivational factors involved with e-cigarette use, 146 
primarily their immediate ability to ameliorate cravings. This study is, to our knowledge, the first 147 
fully-crossed BPD conducted to parse the independent and synergistic influences of both nicotine 148 
delivery and expectancies on craving-related outcomes of e-cigarette use.  149 
 Among dual users, the hypothesized main effect of instructional set was observed upon 150 
reduction in cravings to smoke, which suggests that the craving reduction was driven by 151 
participants’ expectancies about the effects of nicotine rather than the pharmacological properties 152 
of nicotine. The correlation between nicotine dosing estimate and craving reduction provides 153 
further support for the role of expectancies. These results are consistent with contemporary 154 
models and research indicating that drug delivery alone is insufficient for explaining drug 155 
craving and its alleviation (e.g., Baker, Piper, McCarthy, Majeskie, & Fiore, 2004).  Findings are 156 
also consistent with previous BPDs with cigarettes (Juliano & Brandon, 2002), and with a non-157 
BPD study showing that nicotine instructional set influenced craving reduction following use of 158 
nicotine-free e-cigarettes (Copp et al., 2015).  159 
 Notably, the main effect of instructional set rather than drug content is consistent with the 160 
findings from the two extant clinical trials of e-cigarettes for smoking cessation, which both 161 
failed to find statistically superior cessation outcomes from nicotine versus placebo products 162 
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(Bullen et al., 2013; Caponnetto et al., 2013), and it suggests that any therapeutic benefit of e-163 
cigarettes may derive, at least in part, from users’ cognitive expectancies about them.  164 
 Whereas the findings on cravings to smoke address the potential of e-cigarettes as a 165 
substitute for smoking, the effects upon cravings to vape address the maintenance of e-cigarette 166 
use itself.  Here no main effects were found, but an interaction was found between the two 167 
experimental factors that indicated the greatest craving reduction when participants were 168 
accurately told that they were receiving nicotine (i.e. True Positive). The contrast with the 169 
findings on craving to smoke suggest that nicotine delivered via e-cigarettes may reduce cravings 170 
for the same product, but it may not transfer to a different nicotine-delivery product, combustible 171 
cigarettes.  172 
The results of this study should be considered within the context of some methodological 173 
limitations. Both instructional set and, to a lesser degree, actual nicotine dose were found to have 174 
influenced participants’ estimates of the dose they had received. The former finding indicates 175 
that the instructional set manipulation was successful. The latter is not surprising, yet reflects a 176 
common challenge with the BPD (Dar & Barrett, 2014) that must be considered when 177 
interpreting BPD results. Although we collected puff count, additional topography or blood 178 
nicotine measures would have provided more complete data on nicotine delivery.  Several of the 179 
measures used in this study were adapted from validated cigarette measures, but have not yet 180 
been validated specifically for e-cigarettes. Inclusion of a behavioral outcome might have 181 
enhanced the self-report findings. Additionally, it should be noted that the analysis of craving to 182 
vape utilized a larger sample, which may have yielded more stable sample statistics with greater 183 
power.  Finally, the majority of participants used modifiable e-cigarette systems, which may 184 
deliver nicotine more effectively than the standard device used in the study. 185 
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 Emerging evidence suggests that e-cigarettes may be an effective tool for smoking 186 
cessation (Zhu et al., 2017).  The results of the present study suggest that nicotine delivery may 187 
not be necessary for the acute management of cravings to smoke via vaping. Thus, the possibility 188 
of further harm-reduction through the elimination or reduction of nicotine content without 189 
sacrificing e-cigarettes’ potential efficacy for smoking cessation is promising. Public health 190 
campaigns and clinicians could endorse alternative expectancies about the benefits of vaping 191 
upon cigarette craving, reducing the emphasis on nicotine per se.  Moreover, in other domains, 192 
placebo medications have retained their efficacy even after their content has been revealed to 193 
patients (i.e., open-label placebo; Kaptchuk et al., 2010). Future studies should extend this line of 194 
research beyond abstinence-induced craving to those induced by negative affect and conditioned 195 
stimuli (i.e., “smoking triggers”).  196 
197 
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Table 1. Experimental design 
 
 
Instructional Set 
 
 
 
 
 
 
 
 
 
Drug Content 
E-cigarette 
contains nicotine 
E-cigarette does 
not contain 
nicotine 
 
Nicotine 
 
True positive 
 
 
False Negative, 
“Anti-Placebo” 
 
 
 
Non-Nicotine 
 
False positive, 
“Placebo” 
 
True Negative 
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Table 2. Participant demographics (N=128) 
Variable Description Mean (SD) or % 
Age  (range 18-76) 36.40 (13.79) 
Sex Female 38% 
Race Black / African American 12% 
 White / European Origin 83% 
 Other 6% 
Ethnicity Hispanic / Latino 16% 
Marital Status Single 60% 
Sexual Orientation Identify as LGBT+ 13% 
Education High school or less  25% 
 Some College 30% 
 Tech School / Associate’s 29% 
 4-year College Degree or beyond 16% 
Income Under $10,000 22% 
 $10,000 - $29,999 28% 
 $30,000 or more  49% 
 
Note: No significant differences between conditions were found for any of the variables. 
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Table 3. Smoking and vaping characteristics of the full sample, and broken down by current 
smokers (dual users) and former smokers. 
Variable 
Full sample 
(N=128) 
Current 
smokers 
(N=52) 
Former 
smokers 
(N=76) 
p 
Mean cigarettes per day on days smoked (SD)
1
 13.33 (11.31) 8.02 (8.57) 16.96 (11.56) <.001 
Mean days cigarettes smoked per week (SD)
1 
6.01 (1.93) 5.01 (2.35) 6.70 (1.15) <.001 
Mean number of daily e-cigarette uses (SD) 36.50 (53.36) 26.66 (42.40) 43.91 (59.60) n.s 
% reporting vaping continuously all day (SD) 47% 35% 66% .001 
Personal device used
2
:         Disposable, “cig-a-like” 11% 14% 5% n.s 
                                                Refillable tank system 9% 14% 11% n.s 
    Tank system with modifiable electric components 66% 52% 75% n.s 
Mean nicotine content of solution in personal  
     device (mg/ml) 
8.80 (7.51) 10.57 (8.07) 7.71 (6.98) .046 
Flavor used most often:                                Tobacco 11% 17% 7% n.s 
                                           Menthol 21% 21% 21% n.s 
                                          Fruit 41% 40% 42% n.s 
           Other (e.g. custard, dessert, beverages) 23% 12% 30% .013 
Reported e-cigarette initiation to quit smoking 68% 50% 80% <.001 
Flavor requested for ad-lib session:              Tobacco 12% 17% 8% n.s 
                                                         Menthol 25% 25% 25% n.s 
                                                         Fruit 63% 58% 67% n.s 
Mean EDCI 10.05 (4.66) 8.44 (5.10) 11.15 (4.00) .001 
Mean FTND
1
 4.50 (2.89) 3.69 (3.28) 5.05 (2.45) .008 
Notes: 
1
Among former smokers, cigarette quantity, frequency, and dependence reflect reported levels 
prior to quitting smoking. 
2 Personal device used was coded from participants’ self-reported device 
brand/model. Above p values represent significant differences between current and former smokers. n.s = 
not significant. No significant differences were found between conditions on these variables. ECDI = 
Penn State Electronic Cigarette Dependence Inventory. FTND = Fagerström Test for Nicotine 
Dependence. 
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Table 4. Manipulation Effects on Craving: Nicotine, Instruction, and Interactions  
       Condition means Marginal means 
Drug Content 
Marginal  means 
Instructional Set 
 
 
Variable 
True 
Positive Placebo 
Anti-
Placebo 
True 
Negative Nicotine No Nicotine 
Told 
Nicotine 
Told No 
Nicotine 
F 
(Nicotine) 
F 
(Instruction) 
F  
(Nicotine X 
Instruction) 
QSU- Smoke 7.75 8.08 3.93 4.57 5.69 6.19 7.92
a
 4.25
a
 0.15 4.21* 0.02 
Modified QSU-Vape 8.00
a,b
 3.68
a
 3.84
b
 4.82 5.92 4.26 5.87 4.34 1.73 1.31 5.56* 
 
Notes: QSU = 3-item version of Questionnaire of Smoking Urges-Brief.  Positive difference scores represent reductions in value from pre- to post-tests. * p < .05.  Shared 
superscripts indicate significant differences in cell means: a = p < .05, b = p < .01. 
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Figure 1. Manipulation Effects on Desire to Smoke Among Current Smokers (n = 52) 
 
Note: Main effect of instructional set significant at p = .046. Error bars are standard error of the 
mean. 
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Figure 2. Manipulation Effects on Desire to Vape Among Full Sample (N = 128) 
 
 
 
Note: Interaction p = .020. Error bars are standard error of the mean. 
 
 
 
 
 
 
 
